Heartflow reported Q3 2026 revenue of $72.9 million, a 57% year-over-year increase driven by strong U.S. case volume for its FFRCT and Plaque Analysis products. The company significantly raised its full-year 2026 revenue guidance to a range of $262 million to $264 million, citing rapid CCTA market growth and improved production efficiency.
Term
Q3 2026
“Our third quarter was excellent, with revenue accelerating for the third consecutive quarter and U.S. revenue growing at its fastest pace in 11 quarters. Our core FFRCT business remains durable, our installed base continues to expand rapidly, and activations of Heartflow Plaque Analysis are ramping ahead of plan, with utilization broadening across a wider share of applicable CCTAs.”
John Farquhar, President and CEO of Heartflow
“Strong performance across our diagnostic platform, along with disciplined execution of our commercial, innovation and clinical initiatives, gives us the confidence to raise our 2026 guidance once again. With continued momentum and a scaling business, we believe we are well-positioned to extend our market leadership, and we have increased confidence in our path to profitability.”
Arrowhead Pharmaceuticals reported significant revenue from collaborations with Novartis ($89.0 million) and Madrigal ($25.0 million) in fiscal 2026, while total R&D expenses rose 22% to $739.1 million due to pipeline progression. A major one-time operating expense of $215.0 million was recorded for the acquisition of a Priority Review Voucher to accelerate the plozasiran sNDA.
MACOM Technology Solutions Holdings, Inc. identifies significant risks related to environmental compliance, data privacy (GDPR, CCPA, CPRA), and the evolving legal landscape of AI technologies. The company also highlights stock price volatility, noting a 44.2% cumulative decline in mid-2026, and warns of potential dilution from future capital-raising activities.
GeoVax Labs, Inc. reported a net loss of $13.8 million for the nine months ended September 30, 2026, compared to $17.0 million in the prior year period. The company is prioritizing its GEO-MVA vaccine candidate for poxviruses and its Gedeptin oncology program, though both require additional financing to initiate upcoming Phase 3 and Phase 2 trials, respectively.
EWSB Bancorp reported a net loss of $113,655 for the third quarter of 2026, an improvement from a $3.34 million loss in the prior year period which was impacted by a large tax provision. The company strengthened its capital position during the quarter through a stock offering and the issuance of preferred shares, totaling approximately $774,829 in net proceeds.
Vireo Growth Inc. reported a significant revenue increase to $253.7 million for the quarter ended September 30, 2026, compared to $91.7 million in the prior year, driven by multiple acquisitions including Eaze, Hawthorne, and C21. Despite higher gross profits, the company recorded a net loss of $24.0 million for the quarter, impacted by substantial current income tax expenses and transaction-related costs.
Lifeway Foods reported a significant increase in net sales to $197.7 million for the nine months ended September 30, 2026, compared to $157.1 million in the prior year. However, net income decreased to $5.1 million from $11.3 million year-over-year, primarily driven by higher cost of goods sold and increased selling expenses, including a substantial rise in advertising costs.
Smith Micro Software reported Q3 2026 revenue of $5.0 million, a 16% sequential increase and a year-over-year improvement from $4.3 million. The company achieved a five-year high gross margin of 81.6% and significantly narrowed its GAAP net loss to $1.7 million compared to $5.2 million in the prior year's quarter.
Term
Q3 2026
“Our third quarter marked our third consecutive quarter of sequential revenue growth as we continued to build on the momentum established in the first half of the year. Revenue increased 16% sequentially and gross margin rose to 81.6%, a five-year high.”
William W. Smith Jr., president, chief executive officer, and chairman of the board of Smith Micro
“Our pipeline continues to grow and yield high-quality opportunities, and I am confident in our ability to translate this momentum into long-term growth.”
William W. Smith Jr., president, chief executive officer, and chairman of the board of Smith Micro
Andersen Group reported Q3 2026 revenue of $337.3 million, an 18.7% increase year-over-year, driven by broad-based growth across all service lines and geographic regions. The company reported GAAP net income of $68.0 million and introduced full-year 2027 revenue guidance of $1.275 billion to $1.325 billion.
Legacy Education Inc. reported total assets of $86.9 million as of September 30, 2026, compared to $78.5 million at the end of the prior fiscal year. The company's stockholders' equity increased to $54.0 million, driven by growth in retained earnings and additional paid-in capital.
Advanced Biomed Inc. reported a net loss of $989,054 for the quarter ended September 30, 2026, as it transitioned from biotechnology to AI and financial software activities. The company's cash position decreased to $213,995, and it recognized a significant provision for credit losses of $612,636 during the period.
Pluri Inc. reported a significant increase in net loss to $15.39 million for the quarter ended September 30, 2026, primarily driven by a $10.9 million charge for acquired in-process research and development related to the Fishway Transaction. Despite the loss, revenues grew to $759,000 compared to $316,000 in the prior year, and the company successfully raised capital through share issuances and a SAFE agreement.
Avalanche Treasury Corporation reported a net loss of $16.8 million for the nine months ended September 30, 2026, despite a profitable third quarter with net income of $54.6 million driven by changes in the fair value of digital assets. The company's balance sheet shows significant holdings in AVAX and USDC, with total assets decreasing from $190.9 million at year-end 2025 to $151.9 million.
Bank of the James Financial Group reported net income of $9.34 million for the first nine months of 2026, a significant increase from $6.30 million in the same period of 2025, driven by higher net interest income. Total assets grew to $1.06 billion, though stockholders' equity slightly decreased to $78.4 million due to an increase in accumulated other comprehensive loss from unrealized losses on available-for-sale securities.
Noble Roman's reported total revenue of $11.27 million for the nine months ended September 30, 2026, a slight increase from the prior year, though net income decreased from $882,839 to $396,072. The company successfully refinanced its debt, moving the majority of its senior loan obligations from current to long-term liabilities.
Arrowhead Pharmaceuticals reported financial results for its fiscal year ended September 30, 2026, highlighting the commercial launch of REDEMPLO for familial chylomicronemia syndrome (FCS). The company reported 950 cumulative prescriptions since launch and announced that the FDA granted plozasiran entry into the STAR pilot program for severe hypertriglyceridemia, qualifying it for a 6-month priority review.
Term
FY2026
“Arrowhead has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, there is now a company that is beginning to translate promise into real patient outcomes and the potential for durable shareholder value growth.”
Christopher Anzalone, Ph.D., President and CEO
“I believe we approach 2027 with the strongest combination of near-term commercial opportunity and scientific capability in our history.”
KIDZ AI Inc. reported a significant net loss of $7.34 million for the nine months ended September 30, 2026, compared to a $1.64 million loss in the prior year, driven by a $3.38 million fair value loss on crypto assets. Despite the loss, the company significantly strengthened its balance sheet through $10.74 million in private placement capital contributions and the conversion of $9.46 million in debt into equity.
Hartford Creative Group reported total revenues of $2,744,029 for fiscal 2026, a 35% increase driven by its advertising agency business, though net income fell 42% to $641,767 due to a significant credit loss expense and higher income taxes. The company is pivoting toward a mini-drama platform (YYYS App) and is pursuing an uplisting to the Nasdaq Capital Market to fund its estimated $2.0 million in upcoming capital requirements.
AXT, Inc. reported a significant revenue increase to $73.4 million for the third quarter of 2026, up from $28.0 million in the prior year, driven by improved gross margins and operational performance. The company swung to a net income of $25.7 million for the quarter compared to a net loss of $1.9 million in 2025, while its cash position strengthened substantially to $485.5 million following a major common stock issuance.
For the nine months ended September 30, 2026, Akari Therapeutics reported a net loss of $24.1 million, significantly higher than the $12.0 million loss in the prior year period, primarily driven by $12.1 million in impairment losses on goodwill and intangible assets. The company maintained a cash balance of $5.7 million and saw its total shareholders' equity decrease from $28.3 million to $17.5 million during the period.
Intellinetics, Inc. reported a decrease in total assets from $17.3 million at year-end 2025 to $16.7 million as of September 30, 2026. The company's accumulated deficit increased to $26.0 million, while deferred revenues grew significantly to $4.1 million, reflecting shifts in its software-as-a-service and recurring revenue model.
EagleRock Land, LLC is an emerging growth company focused on surface, resource, and water infrastructure assets in the Permian Basin. The filing highlights its recent initial public offering in May 2026 and outlines key operational risks including customer concentration, commodity price volatility, and reliance on surface use agreements.
Yale Transaction Finders, Inc. is a shell company with no revenue, reporting a net loss of $23,521 for the nine months ended September 30, 2026. The company faces substantial doubt about its ability to continue as a going concern, characterized by an accumulated deficit of $1,421,109 and reliance on related-party financing.
SELLAS Life Sciences Group reported a net loss of $10.1 million for the third quarter of 2026, compared to $6.8 million in the prior year period, driven by increased research and development expenses. The company strengthened its balance sheet significantly, ending the period with $134.7 million in cash and cash equivalents following substantial warrant exercises during the nine months ended September 30, 2026.
Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.
“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
Stone Point Credit Corp reported a net increase in net assets from operations of $60.2 million for the nine months ended September 30, 2026, down from $95.2 million in the prior year period. The decrease was primarily driven by $29.6 million in net unrealized depreciation, while net investment income remained relatively stable at $89.3 million.
River Financial Corp reported total assets of $4.09 billion as of September 30, 2026, an increase from $3.79 billion at year-end 2025. The growth was primarily driven by a rise in net loans to $2.89 billion and an increase in total deposits to $3.61 billion.
For the nine months ended September 30, 2026, Brookfield Real Estate Income Trust reported total revenues of $121.4 million, up from $107.8 million in the prior year period. Net income for the nine-month period was $8.7 million, though the company recorded a net loss attributable to stockholders of $0.37 million after accounting for non-controlling interests.
Fundrise eREIT, LLC reported a significant net loss of $11.3 million for Q3 2026, compared to a net income of $5.7 million in the prior year, primarily driven by losses in equity method investees. The company underwent a major merger during the period, resulting in total assets increasing from $274.9 million at year-end 2025 to $791.6 million by September 30, 2026.
For the nine months ended September 30, 2026, the Federal Home Loan Bank of Dallas reported net income of $356.2 million, a decrease from $456.3 million in the prior year period, primarily driven by lower net interest income. Total assets decreased slightly to $106.8 billion from $108.5 billion at year-end 2025, while total capital increased to $6.87 billion.